Previous 10 | Next 10 |
home / stock / seovf / seovf news
(via TheNewswire) LONDON, ONTARIO - TheNewswire - April 21, 2020 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical-stage regenerative medicine therapeutics company, announced today that it is implementing safety measures for its upcoming Annual Meeting of Sharehol...
(via TheNewswire) LONDON, ONTARIO - TheNewswire - March 24, 2020 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine therapeutics company, today provided a corporate update and outlook for 2020. Dr. Philip Toleikis, President a...
(via TheNewswire) LONDON, ONTARIO - TheNewswire - February 17, 2020 - Sernova Corp (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative medicine therapeutics leader announced today that President and CEO Dr. Philip Toleikis will present at NobleCon16 on Fe...
(via TheNewswire) Most advanced subject in the clinical trial continues to show positive indicators of islet function following islet transplant into the Cell Pouch LONDON, ONTARIO - TheNewswire - February 13, 2020 - Sernova Corp (TSXV:SVA)(OTCQB:SEOVF)(FSE:PSH), ...
(via TheNewswire) Ongoing Safety of Sernova's Clinical Trial Confirmed L ondon, Ontario - TheNewswire - February 10, 2020 - Sernova Corp (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage company and leader in regenerative medicine therapeutics is pleased to announc...
Sernova Announces Biotech Veteran as New Chief Financial Officer Canada NewsWire LONDON and ONTARIO, California, Oct. 24, 2019 LONDON and ONTARIO , California , Oct. 24, 2019 /CNW/ -- Sernova Corp. (TSX-V: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical-stage regenerative m...
Vancouver, British Columbia--(Newsfile Corp. - October 17, 2019) - Sernova Corp. (TSXV: SVA) (OTCQB: SEOVF) (FSE: PSH), a clinical stage regenerative medicine company, has reported findings that further validate Cell Pouch™ and therapeutic cell performance in Type-1 diabetes. The Cell P...
(via TheNewswire) Findings further validate Cell Pouch and therapeutic cell performance in Type-1 diabetes LONDON, ONTARIO - TheNewswire - October 16, 2019 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, is pleased to...
(via TheNewswire) LONDON, ONTARIO - TheNewswire - September 17, 2019 - Sernova Corp. (TSXV:SVA) (OTCQB:SEOVF) (FSE:PSH), a clinical-stage regenerative medicine company, announces that it has renewed the engagement of Frontier Flex, an investor relations (IR) and marketi...
(via TheNewswire) LONDON, ONTARIO - TheNewswire - September 10, 2019 - Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH) announces it has completed on Monday a non-brokered private placement of $4.685 million, pursuant to which Sernova issued a total of 23,422,822 Units in...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...